Danaher Corporation $DHR Shares Purchased by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. raised its stake in Danaher Corporation (NYSE:DHR) by 2,345.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 27,731 shares of the conglomerate’s stock after buying an additional 26,597 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Danaher were worth $6,144,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Marquette Asset Management LLC lifted its position in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 73 shares in the last quarter. N.E.W. Advisory Services LLC bought a new stake in shares of Danaher during the second quarter valued at approximately $25,000. Main Street Group LTD acquired a new stake in shares of Danaher in the first quarter valued at approximately $25,000. Field & Main Bank acquired a new stake in shares of Danaher in the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. increased its holdings in shares of Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Up 0.8%

Shares of NYSE DHR opened at $224.65 on Thursday. The firm has a market capitalization of $157.93 billion, a PE ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm’s 50-day moving average is $212.92 and its 200-day moving average is $195.39.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.77 EPS. Equities analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Stifel Nicolaus decreased their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. TD Cowen increased their price objective on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Finally, The Goldman Sachs Group boosted their target price on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.